TW Stock Analysis Is Available! Go Get Discount!

Horizon therapeutics plc

US StockHealth Care

HZNP AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

    Analysis Conclusion

    With insufficient quarterly financial data released by the company, we're unable to provide a rating.

    HZNP Current Performance


    Horizon therapeutics plc


    Avg of Sector



    Top 10 High Relevance to HZNP

    • PTPI Petros pharmaceuticals inc
      Value -Trend 3Swing Trading 2Whale Interest -Dividend 1Market Cap 3.2M
      See more

    HZNP Profile

    Horizon Therapeutics plc is an Ireland-based global biotechnology company. The Company is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Company's portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.

    Price of HZNP